Cargando…

Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies

ABSTRACT: BACKGROUND: Neurotrophic factors are endogenous proteins promoting the survival of different neural cells. Therefore, they elicited great interest as a possible treatment for neurodegenerative disorders, including Parkinson’s Disease (PD). PD is the second most common neurodegenerative dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chmielarz, Piotr, Saarma, Mart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550372/ https://www.ncbi.nlm.nih.gov/pubmed/32700249 http://dx.doi.org/10.1007/s43440-020-00120-3

Ejemplares similares

Neurotrophic Factors in Parkinson’s Disease: Clinical Trials, Open Challenges and Nanoparticle-Mediated Delivery to the Brain
por: Bondarenko, Olesja, et al.
Publicado: (2021)

Increased Serum Levels of Mesencephalic Astrocyte-Derived Neurotrophic Factor in Subjects With Parkinson’s Disease
por: Galli, Emilia, et al.
Publicado: (2019)

Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson’s Disease
por: Garea-Rodríguez, Enrique, et al.
Publicado: (2016)

Cerebral dopamine neurotrophic factor protects and repairs dopamine neurons by novel mechanism
por: Lindholm, Päivi, et al.
Publicado: (2021)

Small Molecules and Peptides Targeting Glial Cell Line-Derived Neurotrophic Factor Receptors for the Treatment of Neurodegeneration
por: Sidorova, Yulia A., et al.
Publicado: (2020)

CDNF Protein Therapy in Parkinson’s Disease
por: Huttunen, Henri J., et al.
Publicado: (2019)

Alpha-synuclein preformed fibrils: a tool to understand Parkinson’s disease and develop disease modifying therapy
por: Chmielarz, Piotr, et al.
Publicado: (2021)

The role of SorLA in neurotrophic activity and complex behavior
por: Glerup, Simon, et al.
Publicado: (2013)

Endoplasmic Reticulum Stress Regulators: New Drug Targets for Parkinson’s Disease
por: Kovaleva, Vera, et al.
Publicado: (2021)

Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Is Highly Expressed in Mouse Tissues With Metabolic Function
por: Danilova, Tatiana, et al.
Publicado: (2019)

Increased circulating concentrations of mesencephalic astrocyte-derived neurotrophic factor in children with type 1 diabetes
por: Galli, Emilia, et al.
Publicado: (2016)

Molecular Dynamics Simulations of the Interactions between Glial Cell Line-Derived Neurotrophic Factor Family Receptor GFRα1 and Small-Molecule Ligands
por: Ivanova, Larisa, et al.
Publicado: (2018)

Cerebral dopamine neurotrophic factor reduces α-synuclein aggregation and propagation and alleviates behavioral alterations in vivo
por: Albert, Katrina, et al.
Publicado: (2021)

Direct Neuronal Reprogramming: Bridging the Gap Between Basic Science and Clinical Application
por: Vasan, Lakshmy, et al.
Publicado: (2021)

Neurotrophic factor therapy for Parkinson's disease: past, present and future
por: Sullivan, Aideen M., et al.
Publicado: (2016)

Neurotrophic factors in Alzheimer's and Parkinson's diseases: implications for pathogenesis and therapy
por: Sampaio, Tuane Bazanella, et al.
Publicado: (2017)

c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease
por: Lindholm, Dan, et al.
Publicado: (2016)

Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) Elevates Stimulus-Evoked Release of Dopamine in Freely-Moving Rats
por: Renko, Juho-Matti, et al.
Publicado: (2018)

MANF Ablation Causes Prolonged Activation of the UPR without Neurodegeneration in the Mouse Midbrain Dopamine System
por: Pakarinen, Emmi, et al.
Publicado: (2020)

Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease
por: Whone, Alan L., et al.
Publicado: (2019)

Bridging the gap between basic science and clinical practice: a role for community clinicians
por: Kahn, Katherine, et al.
Publicado: (2011)

Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2014)

Toxicoepigenetics for Risk Assessment: Bridging the Gap Between Basic and Regulatory Science
por: Le Goff, Anne, et al.
Publicado: (2022)

The Yin and Yang of VEGF and PEDF: Multifaceted Neurotrophic Factors and Their Potential in the Treatment of Parkinson’s Disease
por: Falk, Torsten, et al.
Publicado: (2010)

Bridging the gap between basic science and clinical practice: The role of organizations in addressing clinician barriers
por: Beckett, Megan, et al.
Publicado: (2011)

Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson’s disease
por: Goulding, Susan R., et al.
Publicado: (2021)

The potential of bone morphogenetic protein 2 as a neurotrophic factor for Parkinson's disease
por: Goulding, Susan R., et al.
Publicado: (2020)

Synucleinopathy-associated pathogenesis in Parkinson’s disease and the potential for brain-derived neurotrophic factor
por: Miller, Kathryn M., et al.
Publicado: (2021)

Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson’s disease
por: Zhao, Songyun, et al.
Publicado: (2023)

Serum concentration and clinical significance of brain-derived neurotrophic factor in patients with Parkinson’s disease or essential tremor
por: Huang, Yixian, et al.
Publicado: (2018)

GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson’s Disease
por: Renko, Juho-Matti, et al.
Publicado: (2020)

Bridging the gap between basic science and clinical curricula: lessons from SARS-COV-2 pandemic
por: Cortese, Katia, et al.
Publicado: (2021)

Neurotrophic Factors in Health and Disease
por: Severini, Cinzia
Publicado: (2022)

Disease and the advancement of basic science

Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease
por: Yang, Ting‐Ting, et al.
Publicado: (2021)

Electroacupuncture-regulated neurotrophic factor mRNA expression in the substantia nigra of Parkinson's disease rats
por: Wang, Shuju, et al.
Publicado: (2013)

Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease
por: Whone, Alan, et al.
Publicado: (2019)

Editorial: Bridging the gap between basic neurosciences and clinical neuroimmunology
por: Abbadessa, Gianmarco, et al.
Publicado: (2023)

3475 A TL1 Team Approach to CNS-Localized Delivery of Neurotrophic Factors for Treatment of Parkinson’s Disease
por: Gopinath, Adithya, et al.
Publicado: (2019)

Neuroprotection in Neurodegenerative Disease: From Basic Science to Clinical Applications
por: Monteiro, Marta C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hts8rb2qrl4o3tgti35eetbeqc